Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies-Reference-Cited by-同舟云学术

Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies

Published:2023-01 Issue: Volume:87 Page:100917
ISSN:2212-4926
Container-title:Advances in Biological Regulation
language:en
Short-container-title:Advances in Biological Regulation

Author:

McCubrey James A.^ORCID,Abrams Stephen L.,Follo Matilde Y.,Manzoli Lucia,Ratti Stefano,Martelli Alberto M.,Cervello Melchiorre

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology,Molecular Medicine

Reference78 articles.

1. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma;Abdel-Wahab;J. Hematol. Oncol.,2018

2. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report;Ardalan;CSH mol. case studies,2021

3. Therapeutic application of monoclonal antibodies in pancreatic cancer: Advances, challenges and future opportunities;Arias-Pinilla;Cancers,2021

4. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors;Awada;Melanoma Res.,2022

5. Clinical trial results show promise of targeting autophagy BRAF mutant melanoma;Amaravadi;Autophagy,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer;Cancers;2024-04-20